Navigation Links
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
Date:5/6/2008

en evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

Phase 2 Study Details

The Phase 2 study is a two-arm, randomized, controlled 100-patient trial of first-line treatment of metastatic CRC. The objective of the Phase 2 trial is to compare the safety and efficacy of intravenous picoplatin given once every four weeks in the FOLPI regimen with oxaliplatin in combination with 5- fluorouracil and leucovorin in the modified FOLFOX-6 regimen and to evaluate clinical activity. Poniard expects to generate proof-of-concept data from the Phase 2 trial demonstrating that picoplatin has an improved safety profile. This trial could position picoplatin as the preferred platinum agent for the first-line treatment of metastatic colorectal cancer and could potentially enable a Phase 3 study.

-- Poniard initiated the Phase 2 trial in November 2007 based on clinical

activity and promising safety data observed in its 50-patient, Phase 1

dose-escalation study of picoplatin in the FOLPI regimen as a

first-line treatment for metastatic CRC. Results of the Phase 1 trial

were presented at the ASCO Gastrointestinal Cancers Satellite Symposium

in January and demonstrated that picoplatin has a manageable toxicity

in combination with 5-fluorouracil and leucovorin Picoplatin did not

cause severe neurotoxicity (Grade 3 or higher), as is commonly seen in

metastatic CRC patients treated with oxaliplatin as part of the FOLFOX

regimen. Current National Comprehensive Cancer Network (NCCN) Clinical

Practice Guidelines in Oncology for colon cancer encourage the

discontinuation of FOLFOX after three months of therapy or sooner if

significant neurotoxicity develops (Grade
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
5. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 ... has announced the addition of the  "China ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in China impacted ... in consumption concept, dietary habit, way of ...
(Date:10/17/2014)... 17, 2014 Investor-Edge has initiated ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), ... on these five companies can be accessed at: ... October 16, 2014, ended on a mixed note as ...
(Date:10/17/2014)... BALTIMORE , Oct. 17, 2014  Ameritox SM ... announced the appointment of Thomas Smith , M.D., ... lead a field-based team offering scientific resources for healthcare ... Smith has held leadership positions at a variety of ... will benefit both the pain and behavioral health sides ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... Pharmaceuticals, Inc. announced the appointment of Dave Lemus as ... 2011.  Lemus will join the leadership team at Sigma-Tau ... For the past 13 years, Lemus served as chief ... Segment; TecDAX), one of the Europe,s leading biotechnology companies ...
... Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... indicates that an Abbreviated New Drug Application (ANDA) for ... sulfate) capsules was submitted on March 7, 2011. The ... 2011. Avanir intends to vigorously enforce its ...
Cached Medicine Technology:Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance 2Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 2Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 3Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 4
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
(Date:10/20/2014)... 2014 JZ Fitness, an independently operated ... wellness programming, authorship, international lecturing and community wellness, created ... the release of the JZ Fitness nutrition app, available ... coaching thousands of individuals on nutrition, Jenn Zerling (“JZ”) ... not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... rate since 1999, WASHINGTON, Sept. 11 ... eight years, marking the fourth,consecutive year premium increases ... Published by the Kaiser Family Foundation and ... 2007 Annual Survey found,that health insurance premiums increased ...
... Sept. 11 GlaxoSmithKline (NYSE:,GSK) believes that conclusions ... Nissen et. al. and Furberg et. al. in ... not confirm a difference in the,safety profile of ... that are common to all meta-analyses, by,the authors, ...
... Local Business Community Comes Together in Support of Event, ... still available for the fourth annual Detroit Uncorked, one ... Center, is held at Ford Field, Sept. 28 from ... Motor Company and Ford Field and created and,organized by ...
... Pennsylvania with substantial experience in infection control ... The Pennsylvania,Patient Safety Authority,s Board of Directors ... to help implement Act 52 of 2007. The,act ... in July to help reduce and,eliminate healthcare-associated infections ...
... Journal of the America Heart Association confirms that when young ... influence their heart disease risk later in life. ... have landmark implications on how children should be taught to ... reduction in intake of saturated fat, was found to be ...
... 11 (HealthDay News) -- Carvedilol, a newer member of the beta ... failure, did not help children with the condition, a new study ... it -- was almost exactly the same for 103 young heart-failure ... got a placebo. , "Heart failure in children is both not ...
Cached Medicine News:Health News:Health Insurance Premium Growth Slows for Fourth Straight Year 2Health News:GlaxoSmithKline Responds to JAMA Articles 2Health News:GlaxoSmithKline Responds to JAMA Articles 3Health News:GlaxoSmithKline Responds to JAMA Articles 4Health News:GlaxoSmithKline Responds to JAMA Articles 5Health News:Tickets Still Available for Detroit Uncorked; 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 3Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 4Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 5Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 6Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 7Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 8Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 9Health News:Children who learn heart healthy eating habits lower heart disease risk 2Health News:Children who learn heart healthy eating habits lower heart disease risk 3Health News:Beta Blocker Doesn't Help Children With Heart Failure 2
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits all ... single channel tip cone ...
... best value in high performance electronic pipetting!, ... lightweight design reduce hand fatigue and strain ... tip ejector , Color coding for easy ... for greater performance use Hamilton AdvanTip Low ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
Medicine Products: